TEAS for the Treatment of Pain in Bone Metastases of Lung Cancer

Launched by THE THIRD AFFILIATED HOSPITAL OF ZHEJIANG CHINESE MEDICAL UNIVERSITY · Feb 14, 2023

Keywords

ClinConnect Summary

This clinical trial, called TEAS for the Treatment of Pain in Bone Metastases of Lung Cancer, is looking at a new way to help manage pain in patients who have lung cancer that has spread to the bones. The study will test a treatment called transcutaneous electrical acupoint stimulation (TEAS), which combines two methods: acupuncture and electrical stimulation. The goal is to see if this treatment can effectively reduce pain for patients who are already taking strong pain medications and bone-strengthening drugs.

To participate in the trial, patients need to be diagnosed with non-small cell lung cancer and experience pain related to bone metastases. They should also have stable health and be expected to live for at least three more months. However, people with certain conditions, like severe heart or lung issues, recent surgeries, or specific skin problems, may not be eligible. Participants will receive detailed information about the study and will need to give their consent before joining. This trial is still in the planning stages, so they are not yet recruiting participants.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Fulfilled the diagnostic criteria of non-small cell lung cancer and had a diagnosis of definite bone-metastatic-related pain.
• • Potent opioid analgesics have been prescribed regularly.
• • Bone protective agents (bisphosphonates or desumumab) have been used regularly.
• • Expected survival ≥ 3 months with no obvious contraindication to opioid therapy.
• • Stable vital signs and ECOG-PS score ≤ 2 points; able to cooperate with researchers to complete relevant study evaluations.
• • Signed informed consent.
• Exclusion Criteria:
• • Definitively diagnosed with pain unrelated to lung cancer.
• • Received local radiation therapy or surgery targeting bone metastases within 1 week before enrollment or will receive during the intervention period. The surgery including vertebroplasty, radioparticle implantation, neurological lesions, and other minimally invasive interventions.
• • Venous thrombosis in the upper and lower extremities (below the elbow / knee joint), active cerebrovascular disease, severe cardiopulmonary dysfunction, or those with respiratory depression.
• • Pacemaker implantation or metallic implants in vivo.
• • Skin lesions at the acupoints, poor skin condition, or other situations that are not suitable for treatment with TEAS.
• • Opioid hypersensitivity.
• • Psychiatric disorders or severe cognitive deficits.
• • Participating in other clinical trialists influencing the evaluation of the results of this study.